DRVN
DRVN's fundamental health is lackluster, scoring only 2.4/10. Key concerns include a low current-assets ratio (14.09%) and a high non-current-assets ratio (85.91%), signaling potential liquidity strain. Profitability metrics such as Net profit attributable to parent company shareholders / Net profit (%) are at 100%, but this is offset by weak revenue and cash multiples. Positive aspects are Cash-UP and Asset-MV, yet these are insufficient to elevate the overall rating beyond 'underperform'. Historical factor performance shows mixed returns, with Asset-MV achieving 17.12% monthly returns but Cash-MV yielding -3.99%. The recent €411 million sale of the IMO business helps reduce debt, providing a short-term balance-sheet boost but not a fundamental turnaround.
Analysis Checks(4/10)
- DRVN scores 2.38/10 on fundamentals and holds a Premium valuation at present. Backed by its 16.27% ROE, -8.12% net margin, -10.23 P/E ratio, 3.53 P/B ratio, and -6200.00% earnings growth, these metrics solidify its Underperform investment rating.
